insights_auto
Bakit tumaas ang AXGN 2.85%?
Tingnan ang Higit pang Detalyechevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
$56.95
arrow_upward
+2.85%(+1.58) 1D
$57.00
arrow_upward
+0.09% (+0.050)bedtimePagkalipas ng oras ng trabaho
Sarado: Nob 18, 4:00:01 PM GMT-5 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa AXGN...
Buksan
$55.29
Mataas
$57.58
Mababa
$55.00
Mkt. cap
3.40B
Avg. na dami
1.85M
Dami
2.00
Mataas nang 52-wk
$59.72
Mababa nang 52-wk
$23.61
EPS
-$0.68
Beta
1.21
Mga natitirang share
59.73M
Bilang ng mga empleyado
622
Buksan
$55.29
Mataas
$57.58
Mababa
$55.00
Mkt. cap
3.40B
Avg. na dami
1.85M
Dami
2.00
Mataas nang 52-wk
$59.72
Mababa nang 52-wk
$23.61
EPS
-$0.68
Beta
1.21
Mga natitirang share
59.73M
Bilang ng mga empleyado
622
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
TradingView
·
1 araw ang nakalipas
AXGN: Breast growth accelerates as prostate launch and margin initiatives approach
Investing.com UK
·
1 araw ang nakalipas
AxoGen at Jefferies conference: growth plan faces margin pressure By Investing.com
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Tungkol sa AxoGen, Inc Common Stock
CEO-
Mga Empleyado622
Itinatag2002
HeadquartersAlachua, Florida, Estados Unidos
SektorHealth Care
Industriya-
Websiteaxogeninc.com